Study of Lymphatic Dysfunction in Primary and Secondary Lymphedema — LYMPHODYS  

Lymphedema Clinical Trial

Official title: Study of Lymphatic Dysfunction in Primary and Secondary Lymphedema

Status Not yet recruiting

Clinical Trial Summary

Lymphedema is a disorder of the lymphatic vascular system characterized by impaired lymphatic return and swelling of the extremities and accumulation of undrained interstitial fluid/lymph that results in fibrosis and adipose tissue deposition in the affected area. It can be an inherited condition (primary lymphedema) or occurs after cancer surgery and lymph node removal (secondary lymphedema). It causes a significant morbidity and is a common disabling disease affecting more than 200 million people worldwide, however there is no curative treatment for primary or secondary lymphedema.

Clinical Trial Description

Primary lymphedema is an inherited condition whereas secondary lymphedema develops after cancer treatments. Despite common phenotype, a molecular and histological comparison of these two pathologies has never been performed. Primary lymphedema is associated with heterozygous inactivating mutations of the gene encoding vascular endothelial growth factor C and D receptor (VEGFR-3). Primary lymphedema is rare, affecting 1 in 100,000 individuals. Secondary lymphedema is the most common cause of the disease and affects more than 200 million people worldwide.

Secondary lymphedema occurs months, sometimes years after cancer surgery suggesting that lymphedema is not only a side effect of the surgery, but involves modifications of the lymphatic architecture as well as its microenvironment, in particular adipose tissue that accumulates in the limb.

There is no cure for lymphedema because of the lack of identified therapeutic strategies able to restore collecting lymphatic draining function in the arm or in the leg. The goal will be to establish if these pathologies which possess a common denomination exhibit a similar gene expression. ;

Related Conditions & MeSH terms

• Lymphedema

• NCT number: NCT05629026
• Study type: Interventional
• Source: University Hospital, Toulouse
• Contact: Julie MALLOIZEL-DELAUNAY, MD
• Phone: +33 (0)5 61 32 30 33
• Email: malloizel-delaunay.j@chu-toulouse.fr
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 2024
• Completion date: December 2025